14-Aminocamptothecins: their synthesis, preclinical activity, and potential use for cancer treatment
Jian-Xin Duan1, Xiaohong Cai, Fanying Meng
1Threshold Pharmaceuticals , 1300 Seaport Blvd, Suite 500, Redwood City, California 94063, United States. jduan@thresholdpharm.com
Abstract:
14-Aminocamptothecins were synthesized in good yields by treating camptothecin (1a) and 7-ethylcamptothecin (1b) with 90% fuming nitric acid either neat or in acetic anhydride and then followed by reduction of the resulting 14-nitrocamptothecins (2). 14-Aminocamptothecin (3a) and 7-ethyl-14-aminocamptothecin (3b) demonstrated excellent cytotoxic potency against human tumor cell lines in vitro, and they are not substrates for any of the major clinically relevant efflux pumps (MDR1, MRP1, and BCRP). 3a and 3b showed similar cytotoxicity against human and mouse bone marrow progenitor cells. This is in contrast to many camptothecin analogues, which are substrates for efflux pumps and are dramatically more toxic to human marrow cells relative to murine. 3a and 3b demonstrated significant brain penetration when dosed orally in mice. 3b showed significantly better efficacy relative to topotecan when dosed orally in the three ectopic xenograft models, H460, HT29, and PC-3. On the basis of its favorable in vitro and in vivo profile, 3b warrants future development.
Related Concept Videos
Inhibitors of Bacterial Protein Synthesis
Drugs that Stabilize Microtubules
Inhibition of Cdk Activity
Inhibition of CDK Activity
Drugs that Destabilize Microtubules
C4 Pathway and CAM
C4 Pathway
The C4 pathway is used by plants such as...


